Clinical Trial Update: Cardiometabolic Effects of Eplerenone in HIV Infection [Phase 2]

View source ↗

Summary

Phase 2 study assessing the cardiometabolic effects of eplerenone in HIV infection was terminated, with results posted in July 2018. The conditions studied incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Heart
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Inspra (eplerenone)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cardiac Steatosis, Hepatic Steatosis | Phase 2 | Status: TERMINATED | Results posted: 2018-07-17